Explore

Companies

Drugs

/

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Other/Refractory

Refractory

28

Pipeline Programs↗

51

Active Trials↗

33

Companies Involved↗

Refractory is an emerging landscape with 28 programs across 33 companies. The most active players are Chongqing Precision Biotech Co., Ltd, MaaT Pharma, MingSight Pharmaceuticals, Inc. 2 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

60/100

Pipeline Velocity

36/100

Mech. Concentration

17/100

Completion Rate

66/100

Attrition Rate

17/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved

Phase 3

Phase 2

Phase 1

Preclinical

Key Players

Top Companies

Chongqing Precision Biotech Co., Ltd

2 programs

MaaT Pharma

1 program

MingSight Pharmaceuticals, Inc

1 program

Chengdu FenDi Pharmaceutical Co., Ltd.

1 program

Hebei Senlang Biotechnology Inc., Ltd.

1 program

Pipeline

Programs by Phase

Preclinical3

Mononuclear Cells

National University of Malaysia

Senl-T7

Hebei Senlang Biotechnology Inc., Ltd.

Tamsulosin

Sanofi

Phase 113

Anti-CD19 CAR-NK

Second Affiliated Hospital, School of Medicine, Zhejiang University

FD-001

Chengdu FenDi Pharmaceutical Co., Ltd.

CD19 CAR-T Cells

Chongqing Precision Biotech Co., Ltd

Humanized CD19 CAR-T Cells

Zhejiang University

Anti-BCMA/CD70-CAR-T Cells

The Children's Hospital of Zhejiang University School of Medicine

Phase 210

MS-553, DS1

MingSight Pharmaceuticals, Inc

MB-CART19.1

Miltenyi Biomedicine GmbH

Gecacitinib

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

BK CTL

New York Medical College

Zeprumetostat+azacitadine

Ruijin Hospital

Phase 32

Maat013

MaaT Pharma

Romiplostim

Amgen

Approved

No programs

Analysis

Modality Breakdown

26programs

Small molecule1246%

Cell therapy1142%

Monoclonal antibody28%

Protein / enzyme14%

Modality classified for 100% of 28 pipeline programs.

Analysis

Trial Status

172

clinical trials

Completed56 · 33%

Unknown status35 · 20%

Recruiting33 · 19%

Terminated19 · 11%

Not yet recruiting12 · 7%

Withdrawn10 · 6%

Other7 · 4%

Clinical Trials

Trial Activity

172 trials

A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)

Recruiting·NNanjing IASO Biotechnology Co., Ltd.·Phase 3·NCT06464991·240 enrolled

BGT007 Cells for the Treatment of Refractory Digestive System Tumors

Recruiting·TThe Affiliated Hospital of Xuzhou Medical University·Phase 1·NCT06104241·14 enrolled

Clinical Study of Senl-T7 CAR T Cells in the Treatment of Relapsed and Refractory CD7+ Acute T-ALL/T-LBL

Recruiting·HHebei Senlang Biotechnology Inc., Ltd.·N/A·NCT05626400·100 enrolled

A Study of Humanized CD19 CAR-T Cells Therapy for Patients With Relapsed and/or Refractory B-cell ALL and B-cell NHL

Recruiting·ZZhejiang University·Phase 1·NCT04532268·72 enrolled

Study of BCMA/CD70 CAR-T Therapy for Refractory cSLE

Recruiting·TThe Children's Hospital of Zhejiang University School of Medicine·Phase 1·NCT06934447·18 enrolled

Ruxolitinib Plus Fostamatinib for Steroid Refractory cGvHD

Recruiting·—·Phase 1·NCT06233110·30 enrolled

Clinical Study of Cord Blood-derived CAR-NK Cells Targeting CD19 in the Treatment of Refractory/Relapsed B-cell NHL

Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 1·NCT05472558·48 enrolled

Chimeric Natural Killer Receptor-Universal T Cells for Refractory GVHD

Recruiting·FFujian Medical University·Phase 1·NCT06568328·17 enrolled

Ethanol Gel Versus Steroid in Refractory Lumbar Discogenic Pain

Recruiting·GGelscom SAS·N/A·NCT03415828·230 enrolled

Therapeutic Effects of Hydrogen on Steroid-refractory/or Steroid-dependent cGVHD

Recruiting·NNavy General Hospital, Beijing·Phase 2·NCT02918188·21 enrolled

Study of Therapeutic Efficacy of Anti-CD19 CAR-T Cells in Children With Refractory Refractory AAV

Recruiting·TThe Children's Hospital of Zhejiang University School of Medicine·N/A·NCT06508346·12 enrolled

Sirolimus in the Treatment of Refractory/Relapsed wAIHA

Recruiting·PPeking Union Medical College Hospital·N/A·NCT05925023·22 enrolled

Universal CNK-UT Therapy for Refractory aGVHD

Recruiting·FFirst Affiliated Hospital of Zhejiang University·Phase 1·NCT06750133·23 enrolled

Study of CD19 CAR-T Therapy for Refractory SLE

Recruiting·CChongqing Precision Biotech Co., Ltd·Phase 1·NCT07403097·18 enrolled

CAR T Cells in the Treatment of Refractory and Relapsed CD19+ B Cell Neoplasms

Recruiting·FFamiCordTx·Phase 1·NCT06593145·6 enrolled

Page 1 of 12

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)